On March 28, 2018 Tusk Therapeutics, an immuno-oncology company focused on developing immune-modulating therapeutics by targeting immune cells in cancer, reported that it will deliver an oral presentation and three poster presentations at the 2018 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting taking place from 14th – 18th April 2018 at McCormick Place North/South, Chicago, Illinois, US (Press release, Tusk Therapeutics, MAR 27, 2018, View Source [SID1234525041]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Sergio Quezada, Group Leader and Cancer Research UK Senior Research Fellow at The UCL Cancer Institute, and Chairman of Tusk Therapeutics’ Scientific Advisory Board, will deliver the oral presentation at 10.30am on Monday 16th April. The presentation will focus on Tusk Therapeutics’ first-in-class anti-CD25 antibody programme which is built on novel biology discovered by Tusk Therapeutics in collaboration with Dr. Quezada and his team at University College London. Tusk Therapeutics, Cancer Research UK (via its Commercial Partnerships Team) and UCL announced in 2017, an exclusive licensing and collaboration deal to develop and commercialise antibody-based therapeutics against CD25.

Commenting on the presentations, Luc Dochez, Chief Executive Officer of Tusk Therapeutics said: "We are excited to be presenting data at the upcoming AACR (Free AACR Whitepaper) meeting, in particular, to share data on the unique mechanism behind our anti-CD25 programme. It is well accepted that regulatory T-cells play an important role in immune-suppression in cancer but, thus far, nobody has been able to target Tregs effectively. Based on the pre-clinical proof-of-concept data generated in collaboration with Cancer Research UK and University College London, we

have shown that our novel approach can successfully target Tregs and therefore we believe that Tusk Therapeutics’ anti-CD25 antibody could become an important player in the immuno-oncology field."

​The full list of abstracts accepted for presentation at this year’s AACR (Free AACR Whitepaper) Meeting are detailed below:

Oral Presentation

Title: Targeting regulatory T cells for therapeutic gain: Means and mechanisms
Presenter: Dr. Sergio A. Quezada. University College London Cancer Institute

Session: In Vivo Monitoring of Immunotherapy Responses
Date & Time: April 16, 2018, 10:30 AM – 10:55 AM
Location: N Hall C – McCormick Place North (Level 1)

Poster Presentations

Title: Generation of first-in-class anti-CD25 antibodies depleting Treg without interfering with IL2 signalling for cancer therapies

Abstract: 2787
Session: Therapeutic Antibodies, Including Engineered Antibodies 2

Date & Time: April 16, 2018, 1:00 PM – 5:00 PM
Location: Section 34

Title: A novel approach to deplete Treg cells using non-IL-2 blocking anti-CD25-targeting antibodies leads to complete rejection of established tumors

Abstract: 3143

Session: Immune Cells in the Microenvironment

Date & Time: April 17, 2018, 8:00 AM – 12:00 PM
Location: Section 5

Title: A best in class anti-CD38 antibody with antitumor and immune-modulatory properties

Abstract: 3812

Session: Therapeutic Antibodies, Including Engineered Antibodies 3

Date & Time: Apr. 17, 2018, 8:00 AM – 12:00 PM

Location: Section 34

Full abstracts are available online at www.aacr.org.

For further information, please contact:

Tusk Therapeutics

Luc Dochez, Chief Executive Officer

[email protected]

Media Enquiries:

Consilium Strategic Communications

Julia Wilson, Lindsey Neville

+44 (0) 203 709 5708

[email protected]

On March 27, 2018 -InteRNA Technologies reported that the company will present a poster on its lead microRNA development candidate INT-1B3 at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, to be held in Chicago, IL, on April 14-18, 2018 (Press release, InteRNA Technologies, MAR 27, 2018, View Source [SID1234525017]). The proof-of-concept data highlight INT-1B3’s unique ability to target multiple hallmarks of cancer as a single agent, demonstrating immune system activation, tumor regression and pronounced long term immunity. InteRNA will announce the complete results through a press release following the presentation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Information:
Title: Pharmacologic profile of INT-1B3: a novel synthetic microRNA 193a-3p mimic for therapeutic intervention in Oncology (Abstract #4405)
Presenters: Drs. Sanaz Yahyanejad (Senior Research Scientist) and Michel Janicot (Chief Development Officer)
Session Name: Molecular and Cellular Biology / Genetics – MicroRNA Therapeutics
Date & Time: Tuesday, April 17, 2018; 1:00 pm -5:00 pm Central Standard Time
Location: McCormick Place South, Exhibit Hall A, Poster Section 19, Poster Board Number:6

On March 27, 2018 Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) reported that Paul Chaplin, President & Chief Executive Officer will provide a corporate presentation at Needham & Company’s 17th Annual Healthcare Conference in New York City on Tuesday, March 27, 2018 at 4:00 PM EDT (Press release, Bavarian Nordic, 27 27, 2018, View Source [SID1234525016]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live and archived webcast of the presentation will be available at http://bit.ly/2DZQgOi.

Contacts
U.S.: Seth Lewis, Vice President, Investor Relations. Phone: +1 978 341 5271
Europe: Rolf Sass Sørensen, Vice President Investor Relations & Communications. Phone +45 61 77 47 43

On March 27, 2018 RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal diseases and cancer, reported that two abstracts1 related to the successful Phase III study with BEKINDA (RHB-102)2 24 mg for acute gastroenteritis and gastritis (the GUARD study) have been accepted for oral presentations at the Society for Academic Emergency Medicine (SAEM) 2018 Annual Meeting, May 16-17, 2018, at the JW Marriott Hotel in Indianapolis, IN (Press release, RedHill Biopharma, MAR 27, 2018, View Source [SID1234525013]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The randomized, double-blind, placebo-controlled Phase III GUARD study with BEKINDA 24 mg successfully met its primary endpoint of efficacy in the treatment of acute gastroenteritis and gastritis, and BEKINDA 24 mg was found to be safe and well tolerated in this indication3. If approved for marketing by the FDA, BEKINDA 24 mg could become the first 5-HT3 antiemetic drug in the U.S. indicated for the treatment of acute gastroenteritis and gastritis.

The first presentation, entitled ‘Treatment of Acute Gastroenteritis-Related Emesis with Bimodal Release Ondansetron (RHB-102)’, will be presented by Robert Silverman, MD, MS, Associate Professor of Emergency Medicine, Zucker School of Medicine at Hofstra/Northwell; Northwell Health, and Lead Investigator of the BEKINDA Phase III GUARD study, on Wednesday, May 16, 2018, at 3:00 PM EDT. The abstract concludes that the Phase III GUARD study is the first study of acute gastroenteritis-related emesis showing benefit from any ondansetron preparation in adolescents and adults and suggests that acute gastroenteritis can be treated with a long-acting, bimodal release tablet, potentially avoiding the need for intravenous access.

The second presentation, entitled ‘A 24 mg bimodal-release ondansetron pill (RHB-102) shows no evidence of QT interval prolongation’, will be presented by Joseph Miller, MD, MS, Associate Clinical Professor, Emergency Medicine, Henry Ford Hospital and Investigator of the BEKINDA Phase III GUARD study, on Thursday, May 17, 2018, from 9:00 AM EDT. The abstract concludes that in patients with normal baseline corrected QT interval (QTc), 24 mg bimodal extended-release ondansetron caused no QTc prolongation in comparison to placebo.

About BEKINDA (RHB-102):
BEKINDA is a proprietary, bimodal extended-release (24 hours) oral pill formulation of ondansetron, covered by several issued and pending patents and targets several gastrointestinal indications. A first Phase III clinical study with BEKINDA 24 mg for the treatment of acute gastroenteritis and gastritis (the GUARD study) successfully met its primary endpoint. A Phase II study with BEKINDA 12 mg for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D) successfully met its primary endpoint.

On March 27, 2018 Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, reported that it has entered an agreement with The University Hospitals Cleveland Medical Center, which includes the Seidman Cancer Center and the Cleveland Clinic, to participate in its U.S. Phase I/II clinical trial of Annamycin for the treatment of relapsed or refractory acute myeloid leukemia (AML) and that patient enrollment has begun (Press release, Moleculin, MAR 27, 2018, View Source [SID1234525011]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This is an important milestone in establishing the efficacy of Annamycin in the treatment of AML in a U.S. trial," commented Walter Klemp, Chairman and CEO of Moleculin. "Coupled with the impending Annamycin clinical trial in Poland, we believe we are at an important inflection point to demonstrate the safety and effectiveness of our leading drug candidate. We have worked hard to get to this point, and we are gratified with the opportunities to move Annamycin forward."